Thomas M File.
Levofloxacin in the Treatment of Community-Acquired Pneumonia.
Pak J Chest Med Jan - Mar 2002;8(1):29-36.
.. ..
Levofloxacin is the first fluoroquinolone with enhanced activity against Streptococcus Pneumonia to be marketed in the United States. Because it has in Vitro Activity against all the key respiratory pathogens (including drug-resistant S. pneumoniae and atypical pathogens) it is a promising new addition to our therapeutic armamentarium for community-acquired pneumonia (CAP). The once daily dosing schedule as well as the very high bioavialability offer distinct advantages regarding cost-effective management of CAP. This is a review article.
Category: Pharmacology
Keywords: Levofloxacin. Pneumonia. Respiratory Tract Infections.
Click here for Full Text Article
This article has been viewed 711 times
Download in Citation Manager - Print - Email - PakMediNet Member Services Submit your Research Synopsis for Free Expert analysis - Search- Feedback - Drug Index
Post and View Comments on this Article
